Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The first nucleotide-binding domain (NBD1) is one of two ATP-binding cassette (ABC) domains in the cystic fibrosis transmembrane conductance regulator (CFTR), a protein that functions as a phosphorylation- and ATP-gated chloride channel in epithelial cells. CFTR is unique among ABC transporters because it acts as an ion channel rather than a transporter, with its gating regulated by ATP binding and hydrolysis at the NBDs, and by phosphorylation events. The most prevalent mutation causing cystic fibrosis (ΔF508; deletion of phenylalanine at position 508) occurs within NBD1. This residue lies on an interface thought critical for communication between NBDs and TMDs during gating transitions. Its loss disrupts folding/stability/trafficking/functionality leading to disease phenotype.
ATP binding and hydrolysis modulate CFTR channel gating.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on First Nucleotide-Binding Domain of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR NBD1).